Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nuclectomy

Overview

This study will be a prospective, open-label, multi-center study that will collect safety data for the minimally invasive PerQdisc Nucleus Replacement Device deployed to reduce chronic low back pain.

Full Title of Study: “Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nuclectomy – LOPAIN1″

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 30, 2021

Detailed Description

This study will be a prospective, open-label, multi-center study that will collect safety and efficacy data for the minimally invasive PerQdisc Nucleus Replacement Device (NRD). Patients will have degenerative disc disease (DDD) in one or more lumbar discs. The NRD is used for surgical replacement of a single nucleus pulposus between spinal lumbar discs L1-S1 using an anterior or lateral transpsoas approach. Currently the surgical gold standard involves spinal fusion of the affected vertebral bodies, reducing range of motion and increasing stress on other vertebral bodies. The goal of nucleus replacement is to reduce chronic low back pain by maintaining disc height while preserving range of motion.

Interventions

  • Device: All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
    • All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board. Any patient meeting any of the three intraoperative exclusion criteria will receive an alternative standard of care therapy.

Arms, Groups and Cohorts

  • Experimental: Total Nucleus Replacement
    • All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.

Clinical Trial Outcome Measures

Primary Measures

  • Post surgical change in degree of disability
    • Time Frame: 6 months
    • Patient reported outcomes for degree of disability will be monitored using the Oswestry Disability Index (scale of 0-100). Higher scores indicate greater level of disability.
  • Post surgical change in back pain: Visual Analogue Scale
    • Time Frame: 6 months
    • Patient reported outcomes will be reported using the Visual Analogue Scale (0-100mm). Higher scores indicate greater levels of back pain.

Participating in This Clinical Trial

Inclusion Criteria

  • Patient is skeletally mature and between 21 and 60 years of age. – Patient has Degenerative Disc Disease (DDD) at one or more levels between L1 and S1 – History and clinical findings suggestive of symptomatic DDD: Darkened disc on MRI in T2 weighted images Patients with at least 6 months of low back pain (location defined as the space between the lower margin of the posterior rib cage and horizontal gluteal fold) that is resistant to nonsurgical conservative therapy. – Patient has adequate disc height (~6mm) at the level to be treated – Patient has pre-operative Oswestry Low Back Disability score of greater than or equal to 40 (0-100 scale). – Patient has pre-operative back pain VAS score of greater than or equal to 40 (0-100 scale) – Patient has received conservative, non-surgical treatment for back pain for a minimum of 6 months. – Patient has signed the approved Informed Consent Form. Exclusion Criteria:
  • Patient has had prior lumbar spine surgery – Spinal fusion at any level – Patient has ankylosing spondylitis or other spondyloarthropathy. – Patient has isthmic spondylolisthesis or degenerative spondylolisthesis greater than 2 mm. – Patient has congenital moderate or severe spinal stenosis or epidural lipomatosis. – Patient has significant facet disease. – Patient has had prior lumbar spine surgery – Spinal fusion at any level – Patient has any known active malignancy. – Patient has previously undergone or currently on immunosuppressive therapy. Steroids used to treat inflammation are allowed. – Patient has active local or systemic infection. – Patient has been diagnosed with hepatitis, rheumatoid arthritis, lupus erythematosus, or other autoimmune disease, including AIDS, ARC and HIV. – Patient has diabetes mellitus (Type 1 or 2), requiring daily insulin management. – Patient is pregnant or plans to become pregnant during the course of the study. Pregnancy ruled out by urine or serum HCG. – Patient has a known allergy to silicone (polymer and balloon material) or barium sulfate (polymer). – Patient participated in another investigational drug or device study within the past 30 days. – Patient belongs to a vulnerable population or has a condition such that his/her ability to provide informed consent, comply with follow-up requirements, or provide self- assessments is compromised (e.g. developmentally disabled, prisoner, chronic alcohol/ substance abuser) – Patient has a significant disc herniation at the level to be treated – Patient has a significant Schmorl's node in the level to be treated Intraoperative exclusion criteria:
  • Protrusion of the 20A imaging balloon up to or beyond the outer margin of the vertebra during the imaging steps. – Patient has a violated endplate as determined by imaging balloon during fluoroscopy – Patient has a disc space that is too narrow for implantation.
  • Gender Eligibility: All

    Minimum Age: 21 Years

    Maximum Age: 60 Years

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • Spinal Stabilization Technologies
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Official(s)
      • Michael Hess, MD, Study Chair, London Spine Clinic/ATOS-Klinik
    • Overall Contact(s)
      • Jeffrey Griebel, 800-484-1588, jgriebel@sstspine.com

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.